Application value of soluble C5b-9 in the diagnosis of delayed graft function after kidney transplantation
10.12464/j.issn.1674-7445.2026135
- VernacularTitle:可溶性C5b-9在肾移植术后移植物功能延迟恢复诊断中的应用价值
- Author:
Lihong SHANG
1
;
Zhihua WANG
1
;
Wenyan ZHANG
1
;
Jiaoxia LIANG
1
;
Mingjun WANG
2
;
Ning LI
2
;
Shaohua SHI
2
;
Linru ZHU
1
Author Information
1. Department of Laboratory (Nephrology Laboratory), the Second People’s Hospital of Shanxi Province, Taiyuan 030012, China.
2. null.
- Publication Type:OriginalArticle
- Keywords:
Kidney transplantation;
Delayed graft function;
Complement;
sC5b-9;
Primary nonfunction graft;
Graft loss;
Eculizumab;
Serum creatinine
- From:
Organ Transplantation
2026;17(5):757-764
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the diagnostic value of soluble C5b-9 (sC5b-9) for delayed graft function (DGF) following kidney transplantation. Methods Clinical data of 49 kidney transplant recipients who underwent sC5b-9 detection at the Second People’s Hospital of Shanxi Province between January 2024 and December 2025 were retrospectively analyzed. Recipients were divided into the DGF group (n=25) and the non-DGF group (n=24) according to the occurrence of DGF. Baseline characteristics and serum sC5b-9 levels were compared between the two groups. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic efficacy of sC5b-9 for DGF. A restricted cubic spline model was adopted to investigate the association between sC5b-9 and DGF. Results Among the 49 recipients, DGF occurred in 25 patients. Compared with the non-DGF group, the DGF group presented a higher proportion of male patients, a higher incidence of adverse transplant outcomes, and elevated final serum creatinine levels (all P<0.05). Within 30 days after transplantation, sC5b-9 concentrations were significantly higher in the DGF group than those in the non-DGF group (P<0.001). ROC analysis revealed that the area under the curve (AUC) of sC5b-9 for diagnosing DGF was 0.81, with a 95% confidence interval (CI) of 0.68-0.92, and the optimal cutoff value was 265.7 ng/mL. Recipients with elevated sC5b-9 (≥265.7 ng/mL) had a significantly higher incidence of DGF than those with low sC5b-9 levels (<265.7 ng/mL) (P<0.001). Recipients with adverse outcomes exhibited significantly higher sC5b-9 levels than those without adverse outcomes (P<0.001), and the AUC of sC5b-9 for identifying adverse outcomes was 0.82 (95%CI 0.63-0.95). A significant nonlinear correlation was observed between sC5b-9 and final serum creatinine (P<0.001). Conclusions Elevated sC5b-9 is correlated with the development of DGF after kidney transplantation and exhibits favorable diagnostic performance. It may serve as a potential biomarker for predicting early allograft dysfunction and adverse outcomes in kidney transplant recipients.
